Dr. Reddy’s Laboratories announces the launch of Penicillamine Capsules USP, 250 mg in the U.S. Market
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Penicillamine Capsules USP, 250 mg, a therapeutic equivalent generic version
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Penicillamine Capsules USP, 250 mg, a therapeutic equivalent generic version of Cuprimine® (penicillamine) Capsules, 250 mg, approved by the U.S. Food and Drug Administration (USFDA).
The Cuprimine® brand and generic market had U.S. sales of approximately $80 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.
Dr. Reddy’s Penicillamine Capsules, USP is available as 250 mg capsules in a bottle count sizes of 100.
Please click here for prescribing information including boxed warning.
|
Warnings
Physicians planning to use penicillamine should thoroughly familiarize themselves with its toxicity, special dosage considerations, and therapeutic benefits. Penicillamine should never be used casually. Each patient should remain constantly under the close supervision of the physician. Patients should be warned to report promptly any symptoms suggesting toxicity.
|
Cuprimine® is a trademark of Bausch Health Companies Inc.
